Dossier
biotechs
Coverage of biotechs in the Nexus archive.
GUARDtopic1Medicare Part Dtopic1rare disease drugstopic1Trump administrationorganization1AstraZenecaorganization1Bristol Myers Squibborganization1most-favored nationtopic1alpha-1 antitrypsin deficiency (AATD)topic1U.S. drug industryorganization1Chinese drug industryorganization1patent warstopic1alpha-1 antitrypsintopic1
- STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
A Medicare pilot program called GUARD, aimed at lowering drug prices through 'most-favored nation' pricing, could lose significant savings if rare disease drugs are excluded, according to biotech lobbying efforts. Additionally, reports of potential mergers between AstraZeneca and Bristol Myers Squibb have been denied by anonymous sources.
- From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
Biotechs are investing billions to develop a cure for alpha-1 antitrypsin deficiency (AATD), a rare liver disorder caused by a DNA mutation. The race involves U.S. and Chinese drug industries competing with dueling technologies, patent disputes, and a fractured alliance, highlighting intense global competition.